The FDA has selected seven companies, including Eli Lilly and Regeneron, for the 'PreCheck' pilot program. The initiative allows regulators to review new manufacturing facilities during construction, potentially saving up to 14 months. Eligible facilities must address market supply gaps or unmet medical needs, focusing on complex biologics and genetic medicines.